Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | hypothetical protein | 0.0053 | 0.0847 | 0.0847 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0062 | 0.124 | 0.124 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0062 | 0.124 | 0.0429 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0133 | 0.447 | 0.447 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0195 | 0.7253 | 0.6998 |
Schistosoma mansoni | tar DNA-binding protein | 0.0199 | 0.7429 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0199 | 0.7429 | 0.7191 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0053 | 0.0847 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0053 | 0.0847 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0195 | 0.7253 | 0.7253 |
Echinococcus granulosus | tar DNA binding protein | 0.0199 | 0.7429 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0199 | 0.7429 | 1 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0256 | 1 | 1 |
Brugia malayi | TAR-binding protein | 0.0199 | 0.7429 | 0.7429 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0195 | 0.7253 | 0.7253 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0053 | 0.0847 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0133 | 0.447 | 0.3958 |
Loa Loa (eye worm) | TAR-binding protein | 0.0199 | 0.7429 | 0.7191 |
Schistosoma mansoni | tar DNA-binding protein | 0.0199 | 0.7429 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0199 | 0.7429 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0053 | 0.0847 | 0.5 |
Brugia malayi | RNA binding protein | 0.0199 | 0.7429 | 0.7429 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0256 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0133 | 0.447 | 0.5218 |
Schistosoma mansoni | tar DNA-binding protein | 0.0199 | 0.7429 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0053 | 0.0847 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0199 | 0.7429 | 0.7191 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0053 | 0.0847 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0062 | 0.124 | 0.0429 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0062 | 0.124 | 0.124 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0053 | 0.0847 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0195 | 0.7253 | 0.6998 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0199 | 0.7429 | 0.7429 |
Schistosoma mansoni | tar DNA-binding protein | 0.0199 | 0.7429 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0053 | 0.0847 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (binding) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 70.7946 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488939] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.